Ann Arbor, MI, December 7, 2016 – Swift Biosciences held two highly regarded Corporate Workshops at the AMP 2016 Annual Meeting (Nov 9, 2016, Charlotte, NC) highlighting the use of NGS technologies for FFPE and liquid biopsy samples. Industry-leading speakers presented on Swift’s behalf. View all presentations.
Maximizing the Potential of FFPE Samples with Targeted NGS Panels
- Promega DNA QC Assay: Strategies for Predicting Downstream NGS Success with FFPE Samples. By Curtis Knox, Strategic Marketing Manager, NGS, Promega Corporation
- DEPArray™ Technology: Bringing Precision to Precision Medicine. By Nicolo Manaresi, PhD, Chief Scientific Officer, Silicon Biosystems SpA
Utilizing ctDNA and CTCs from Liquid Biopsy Samples for Cancer Prediction
- Mutation Profiling of Uterine Lavage Fluid: Detection of Early Stage Endometrial Cancers and an Unexplored Landscape of Driver Mutations in Women “Without Cancer”. By John Martignetti, PhD, MD, Network Director, Laboratory of Translational Research, The Mount Sinai Hospital
- Ultra-Sensitive Sequencing for Liquid Biopsy Samples. By Cristian Ionescu-Zanetti, PhD, CTO and Co-Founder, Fluxion Biosciences